On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
|Articles|July 23, 2012
Global AIDS Conference Rally Calls for Cheaper Medicines, More Funding
Advertisement
The first International AIDS Conference to be held in the United States in more than two decades opened Sunday with repeated assertions that the 31-year-old epidemic can be realistically brought to an end with more money and attention, strategically applied.
The money is needed to put millions more of the world’s 34 million HIV-infected people on medication, with special attention to those most at risk of getting and transmitting the virus — male homosexuals, drug users and the poor.
Read the full story:
Source: The Washinton Post
Advertisement
Related to this article
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
Advertisement
Advertisement
Trending on AJMC
1
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
2
5 Things to Know About the One Big Beautiful Bill Act
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
5